SCHEMBL2768004

SCHEMBL2768004

O=C(O)c1cccc2c1CCc1cccc3[nH]nc-2c13

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.52
MAPK9 P45984 2/20 0.52
MAPK10 P53779 2/20 0.52
GSR P00390 2/20 0.48
KDM4E B2RXH2 5/20 0.43
HSD17B10 Q99714 4/20 0.43
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 3/20 0.43
KIT P10721 3/20 0.43
FLT3 P36888 3/20 0.43
CYP2C9 P11712 2/20 0.43
MEN1 O00255 2/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 2/20 0.43
PLK4 O00444 2/20 0.43
AURKA O14965 2/20 0.43
ROCK2 O75116 2/20 0.43
CHEK2 O96017 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2768870 0.83 GSR (0.56) MAPK8MAPK9MAPK10GSRKDM4E
SCHEMBL2768161 0.82 KDR (0.50) MAPK8MAPK9MAPK10KDM4EHSD17B10
SCHEMBL2771305 0.81 MAPK8 (0.57) MAPK8MAPK9MAPK10GSRKDM4E
SCHEMBL2769418 0.80 ABL1 (0.46) MAPK8MAPK9MAPK10KDM4EHSD17B10
SCHEMBL2768700 0.79 MAPK10 (0.52) MAPK8MAPK9MAPK10GSRKDM4E
SCHEMBL2768727 0.79 MAPK8 (0.52) MAPK8MAPK9MAPK10GSRKDM4E
SCHEMBL2769394 0.78 MAPK10 (0.76) MAPK8MAPK9MAPK10GSRKDM4E
SCHEMBL2769382 0.77 NPC1 (0.44) MAPK8MAPK9MAPK10GSRKDM4E
SCHEMBL2771632 0.77 MAPK8 (0.44) MAPK8MAPK9MAPK10KDM4EHSD17B10
SCHEMBL2768451 0.77 NPSR1 (0.47) MAPK8KDM4EHSD17B10ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-20060111419-A1 Novel fused indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-25 US disclosed
EP-1479670-A1 NOVEL FUSED RING INDAZOLE COMPOUNDS Eisai Co., Ltd. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111419-A1 Novel fused indazole compounds MAP2K3, MAP3K11, MAP2K2 MAPK8 38/4885MAPK9 42/4885MAPK10 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.